Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.40 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4432950 | 1.00 | AOC3 (0.52) | AOC3KDM4EIGF1RPTPN1HTT | |
| SCHEMBL16337268 | 1.00 | AOC3 (0.52) | AOC3KDM4EIGF1RPTPN1HTT | |
| SCHEMBL21353904 | 0.81 | AOC3 (0.44) | AOC3KDM4EIGF1RPTPN1HTT | |
| SCHEMBL21353903 | 0.81 | AOC3 (0.44) | AOC3KDM4EIGF1RPTPN1HTT | |
| SCHEMBL21393419 | 0.80 | AOC3 (0.47) | AOC3KDM4ESLC6A4SLC6A3MEN1 | |
| SCHEMBL21363635 | 0.80 | AOC3 (0.47) | AOC3KDM4EIGF1RHTTSLC6A4 | |
| SCHEMBL1155019 | 0.78 | AOC3 (0.53) | AOC3KDM4EIGF1RHTTGABBR2 | |
| SCHEMBL6481591 | 0.78 | AOC3 (0.53) | AOC3KDM4EIGF1RHTTGABBR2 | |
| SCHEMBL16340559 | 0.78 | AOC3 (0.53) | AOC3KDM4EIGF1RHTTGABBR2 | |
| SCHEMBL83311 | 0.78 | HTR2A (0.45) | IGF1RSLC6A4SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400504-A1 | THIOPHENE RING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences (CN) | 2024-07-17 | — | — | EP | disclosed |
| CN-114072398-B | Compounds that inhibit TDG activity | 上海仕谱生物科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-114072398-A | Compounds that inhibit TDG activity | 上海仕谱生物科技有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-111909138-A | Compounds that inhibit TDG activity | 上海仕谱生物科技有限公司 | 2020-11-10 | — | — | CN | disclosed |
| CN-104961626-B | A kind of preparation method of hydroxyl bromine compounds | 中国科学院化学研究所 | 2016-09-21 | — | — | CN | disclosed |
| CN-104961626-A | Hydroxyl bromine compound preparation method | CHINESE ACAD INST CHEMISTRY | 2015-10-07 | — | — | CN | disclosed |
| CN-101747211-A | Synthesis method of derivative of chiral Beta-amino-alcohol and part of final products thereof | ASYMCHEM LIFE SCIENCE TIANJIN | 2010-06-23 | — | — | CN | disclosed |
| US-6878705-B2 | 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents | PFIZER (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY | 2004-12-23 | — | — | US | disclosed |
| EP-1465895-A2 | 4-OXO-4,7-DIHYDROFURO(2,3-B)PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-0735142-B1 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICALS CO LTD (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-6156940-A | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 2000-12-05 | — | — | US | disclosed |
| EP-0713848-B1 | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS COMPANY (JP) | 1999-09-08 | — | — | EP | disclosed |
| US-5841001-A | ALLOWING 2-HALO-1-(SUBSTITUTED PHENYL)ETHANOL TO CONTACT ENZYME STEREOSELECTIVELY CATALYZING ESTER INTERCHANGE IN PRESENCE OF CARBOXYLIC ANHYDRIDE | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-11-24 | — | — | US | disclosed |
| US-5831132-A | REDUCING AGENT FROM BORANES AND AMINO ALCOHOLS | SUMIKA FINE CHEMICALS COMPANY, LTD. (JP) | 1998-11-03 | — | — | US | disclosed |
| US-5717116-A | TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0792936-A2 | Process for the preparation of optically active 2-halo-1-(substituted phenyl) ethanol | Mitsubishi Chemical Corporation (JP) | 1997-09-03 | — | — | EP | disclosed |
| EP-0735142-A2 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0713848-A1 | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS Company, Limited (JP) | 1996-05-29 | — | — | EP | disclosed |
| EP-0065354-A1 | Process for the preparation of 1,1-bis phenyl-2-haloalkan-1-ols | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | IL4, ZC3HAV1, IRF3 | AOC3 3745/4885KDM4E 42/4885IGF1R 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.